Boule Diagnostics AB

As of June 30, 2026, Boule Diagnostics AB carries a market capitalization of 144.07M, placing it among publicly traded companies globally. Its enterprise value stands at 351.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Boule Diagnostics AB's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Boule Diagnostics AB has 38.83M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Boule Diagnostics AB maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Boule Diagnostics AB recorded 3.20M in income tax expense.

As of the close on October 22, 2026, Boule Diagnostics AB's stock has declined approximately 58.84% over the past 52 weeks. The 50-day moving average sits at 2.67, while the 200-day moving average is 3.63.

As of June 30, 2026, Boule Diagnostics AB holds 19.60M in cash and equivalents against 227.30M in total debt, resulting in a net debt position of 168.10M. Total book value stands at 174.90M, with working capital of 15.30M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Boule Diagnostics AB's most recent stock split took place on November 9, 2022 with a 131:185 split ratio.